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The present study was aimed to assess the neuropharmacological properties of the novel 
Benzopyran-2-one (coumarin) derivatives i.e., 7-(2-(m-nitro)-phenyl thiazolidinyl)-4-methyl 
benzopyran-2-one (comp-I), 7-(2-(o,p-dichloro)-phenyl thiazolidinyl)-4-methyl-benzopyran-
2-one (comp-II) and 7-(2-(p-methyl)-phenyl thiazolidinyl)-4-methyl-benzopyran-2-one 
(comp-III) by using the various pharmacological activities i.e., anticonvulsant, anxiolytic, 
spontaneous motor activity, skeletal muscle relaxant and analgesic activities along with 
assay of serum gamma amino butyric acid (GABA) levels. Methods: Investigation of all 
neuropharmacological profiles were evaluated by performing the various pharmacological 
activities using the different screening models, i.e., anticonvulsant activity by 
pentylenetetrazole (PTZ) induced seizure model, anxiolytic activity (exploratory behaviour) 
by evasion test, assay of GABA levels after anticonvulsant model was performed by using 
chromatographic technique, spontaneous motor activity (SMA) by actophotometer test, 
skeletal muscle relaxation by rotarod test and analgesic activity by Eddy’s hot plate and 
Haffner’s tail clip methods in Wistar albino mice. Results: All the Benzopyran-2-one 
derivatives showed significant anticonvulsant activity by prolonging the onset of seizures and 
reducing the duration of seizures and mortality rate when compared with control group. The 
test compounds showed significant anxiolytic effect. The serum GABA levels were 
significantly elevated in the treated groups, when compared with that of control group. The 
test compounds showed significant decrease in the spontaneous motor activity. The test 
compounds significantly showed a skeletal muscle relaxation after 30 min of dosing. The test 
compounds showed significant increase in paw licking time to heat stimuli in hot plate 
method and increase in the reaction time of mice to dislodge the clip. Conclusion: The 
present study has revealed that all the Benzopyran-2-one derivatives possess significant 
neuropharmacological properties confirmed by anticonvulsant, anxiolytic, skeletal muscle 
relaxant, analgesic effects and decrease in spontaneous motor activity at a dose of 20 mg/kg 
p.o. in swiss albino mice. 
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INTRODUCTION 
One of the foremost problems in the 
treatment of central nervous system (CNS) 
disorders is the selective delivery of the 
therapeutic agent to the affected cells [1]. 
The management of neurological and 
psychiatric disorders is a vast and evolving 
area for researchers, primary care 
physicians and specialists [2]. These 
disease states, including depression, 
epilepsy, neurodegenerative disorders, 
neuropathic pain, multiple sclerosis (MS) 
and schizophrenia are complicated 
disorders affecting mood, memory and 
mobility: the true essence of being [3]. The 
availability and use of drugs with 
demonstrable efficacy in psychotic 
disorders has grown since the late 1950s to 
the point that 10% to 15% of prescriptions 
written in the U.S are of medications 
intended to affect mental processes, to 
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mood, thinking or behavior [4]. 
Schizophrenia is a devastating psychiatric 
illness that affects ~ 1% of the population 
worldwide [5]. Alzheimer disease (AD) is 
a major public health issue with a 
prediction of 12 millions Americans being 
affected by 2025 [6]. Depression is 
currently one of the leading causes of 
disability on the global burden of disease 
list worldwide and is predicted to rank 
second by the year 2020 [7]. The 
development of medications for the 
treatment of CNS disorders is based on 
careful assessment of adverse effects as 
well as efficacy [8]. Besides addiction 
liabilities, benzodiazepines adversely 
affect the respiratory, digestive and 
immune system of body and the chronic 
treatment with benzodiazepines often 
prove more harmful in the longer run [9]. 
To achieve the substantial improvement in 
the treatment of CNS illness, two factors 
need to be considered: (i) Identification of 
the underlying mechanism of the CNS 
defects and, (ii) Selective drug delivery to 
limit potential side-effects. 
Neuropharmacology is understanding the 
actions of drugs on the functions of the 
brain, whether it be on single cells or 
behavior, is a multilevel, multifaceted 
process that begins with and builds upon 
the concept of molecular interactions [10]. 
These drugs may originate from plants, 
minerals or synthetic derivatives. Changes 
in mood, thinking and behavior may be 
mediated by interaction of these drugs 
with particular target sites or receptors 
found in the nervous system [11]. Recently 
coumarins have evoked a great interest in 
neuropharmacological research and have 
been found effective in CNS. Review of 
literature shows that natural plants 
containing coumarins as an active 
constituent such as Petiveria alliacea, [12] 
Torresea cearensis ,Eclipta alba, Pterodon 
polygaliflorous and Hybanthus 
ipecacuanha a group of Brazilian 
medicinal plants, [13] Leucas inflate, [14] 
Angelica gigas, [15] Ficus platyphylla, 
[16] Careya arborea, [17] Morus alba L 
(mulberry) [18] and prenyloxycoumarins 
[19] have been reported for CNS activities. 
Chemically synthesized benzodiazepine 
derivatives from coumarins have been 
reported for antianxiety activity [20]. 
Thiosemicarbazido derivatives of 
coumarin for a potential anticonvulsant 
and analgesic activity have been reported 
earlier [21]. Some bi-heterocyclic 
coumarin derivatives are reported to have 
analgesic and anti-inflammatory activities 
[22]. Some substituted coumarins are also 
reported for anticonvulsant activity [23]. 
Therefore, we can conclude that any plant 
extract or chemically synthesized 
derivatives containing coumarin may show 
neuropharmacological effects i.e., action 
on CNS. Hence, the present study deals 
with the investigation of the 
neuropharmacological effects such as 
analgesic effect, spontaneous motor 
activity (SMA), anxiolytic, skeletal muscle 
relaxant and anticonvulsant activities of 
some novel Benzopyran-2-one (coumarin) 




(comp-II) and 7-(2-(p-methyl)-phenyl 
thiazolidinyl)-4-methyl-benzopyran-2-one 
(comp-III) in mice. 
 
REVIEW OF LITERATURE 
Coumarin, the simplest member of the 
group of oxygen heterocycle called 
benzopyran-2-one, occur naturally in 
plants, microorganisms and naturally 
occurring phenolic substance. These are 
composed of fused benzene and pyrone 
rings which may be considered, to be 
lactones of the 2-hydroxy-Z-cinnamic 
acid. Coumarins owe their class name to 
‘coumarou’ the vernacular name of tonka 
bean (Dipteryx odorata Wild. Fabaceae), 
from which coumarin itself was isolated in 
1820 [24, 25]. Coumarin is present in wide 
variety of plants including cassia, 
lavender, yellow sweet clover, fruits (e.g. 
bilberry and cloudberry) green tea and 
chicory [26]. Over one thousand 
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simplest among them are widely 
distributed in all of the vegetable kingdom. 
With MW: 146.14 and Formula: C9H6O2. 
Physical properties [27] include Physical 
state: colourless flakes, with characteristic 
odour, Melting point: 68-70 oC, Density: 
0.94 g/cm3 and poor Solubility in water. 
Literature survey reveals that natural 
plants containing coumarins show various 
biological activities such as antimicrobial, 
[28] cytotoxic, [29, 30] antibacterial, [31] 
antiulcerogenic, [32] antitumor promoting 
effect, [33] antifungal, [34] antioxidant, 
[35, 36] anti proliferative effect, [37] anti-
inflammatory and analgesic, [38, 39] 
antispasmodic and bronchodilator, [40] 
hypotensive, [41] antidiabetic, [42] 
vasodilator, [43] antiedema, [44] 
photosensitizing, [45] antiamoebic, [46] 
hepatoprotective, [47] sedative and 
hypnotic, [48] anxiolytic [49] and 
antimalarial activity [50]. Coumarins are 
also used in many cosmetic products [51]. 
Chemically synthesized derivatives of 
coumarin have also been reported to show 
CNS activities such as anxiolytic, [20] 
anticonvulsant [21] and analgesic activities 
[22]. Literature survey reveals that along 
with the biological activities on CNS, 
coumarin derivatives with diverse 
structural features show versatile 
pharmacological effects such as 
antimicrobial, [52] anti-cancer, [53] anti-
tubercular, [54] anti-inflammatory, [55] 
anti-HIV, [56] anti-mycobacterial, [57] 
anti-fungal, [58] anti-filarial, [59] anti-
coagulant [60] and anti-ulcer [61] 
activities. Chemically synthesized 
derivatives of coumarin have also been 
reported to show various other biological 
activities such as antifungal, [62] 
microtubule inhibitor with antimitotic 
activity in multidrug resistant cancer cells, 
[63] antiinflammatory, [64] anticandida, 
[65] MAO-B inhibitor, [66] antiprotozoal, 
[67] antioxidant, [68, 69] Gyrase B-
inhibitor, [70] 5-lipoxygenase inhibitor, 
[71] inhibitor of heat shock protein 90 
(HSP 90), [72] inhibitor of multi-drug 
transporter P-glycoprotien, [73] allosteric 
MEK1 inhibitor [74] and xanthine oxidase 
inhibitors [75]. Along with this, synthetic 
coumarin derivatives are also used as 
acidichromic colorant [76].  
 
MATERIALS AND METHODS 
Animals (Wistar albino mice) weighing 
20-25gm were procured from the animal 
house of K.L.E.Society’s College Of 
Pharmacy, Hubli, Karnataka and were 
used for the study. The animals were 
housed under standard 12-h light/dark 
cycle and were kept for one week to 
acclimatize to laboratory conditions before 
starting the experiment. They were given 
free access to water and standard feed, 12h 
prior to an experiment; the mice were 
deprived of food but not water.  
The test compounds used for the present 
study were synthesized according to the 
method of Ronad et.al. [77], i.e.,7-(2-(m-
nitro)-phenyl thiazolidinyl)-4-methyl 
benzopyran-2-one (comp-I), 7-(2-(o, p-
dichloro)-phenyl thiazolidinyl)-4-methyl-




Toxicity Studies  
Acute oral toxicity – Acute toxic class 
method 
The acute oral toxicity study was carried 
out as per the guidelines set by 
Organization for Economic Co-operation 
and Development (OECD), [78] revised 
draft guidelines 423, revised from 
Committee for the Purpose of Control and 
Supervision of Experiments on Animals 
(CPCSEA), Ministry of Social Justice and 
Empowerment, Government of India. 
Approval of the Institutional Animal 
Ethical Committee was obtained prior to 
the experimentation on animals. Acute 
toxicity studies were performed on female 
Wistar mice weighing between 20-25gm. 
Mice were fasted overnight prior to the 
experimental up and down procedure. 
Animals were observed individually after 
dosing at least once during first 30 min, 
periodically during first 24 h with special 
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symptoms such as salivation, lacrymation, 
tremors, respiratory distress, convulsions, 
death etc. The maximum nonlethal dose 
was found to be 200 mg/kg body weight, 
hence 1/10 th dose was taken as effective 
dose (i.e., 20 mg/kg) for all three 
benzopyran-2-one (coumarin) derivatives 
i.e, 7-(2-(m-nitro)-phenyl thiazolidinyl)-4-
methyl benzopyran-2-one (comp-I), 7-(2-
(o,p-dichloro)-phenyl thiazolidinyl)-4-
methyl-benzopyran-2-one (comp-II) and 7-
(2-(p-methyl)-phenyl thiazolidinyl)-4-
methyl-benzopyran-2-one (comp-III) for 
investigation of neuropharmacological 
activities such as spontaneous motor 
activity, anti-anxiety activity, skeletal 
muscle relaxant activity, anticonvulsant 
activity and analgesic activity. 
 
Anticonvulsant Activity 
Pentylenetetrazole (PTZ) induced 
siezures 
Wistar albino mice of either sex weighing 
between 20-25 g were divided into five 
groups, i.e., Group-I: Control – 1 % 
sodium CMC + PTZ (5 ml/kg p.o. + 90 
mg/kg body weight i.p.),Group-II: 
Standard - Diazepam (1 mg/ kg body 
weight, p.o.),Group-III: Compound-I (20 
mg/kg body weight, p.o.),Group-IV: 
Compound-II (20 mg/kg body weight, 
p.o.),Group-V: Compound-III (20 mg/kg 
body weight, p.o.). Mice were treated with 
either Benzopyran-2-one derivatives i.e. 
comp-I, comp-II and comp-III (20 mg/kg 
p.o.) or normal (1% sodium CMC, 5 ml/kg 
p.o.) or standard drug Diazepam (1mg/kg 
p.o.).They were all given PTZ (90 mg/kg 
i.p.) 60 min later and observed for the 
seizures. The time taken for the onset of 
seizures and the duration of seizures was 
noted. The percentage of animals protected 
(not showing convulsion) within 60 min 





Wistar albino mice of either sex weighing 
between 20-25 g were divided into five 
groups, i.e., Group-I: Control – 1 % 
sodium CMC (5 ml/kg p.o.),Group-II: 
Standard - Diazepam (1 mg/ kg body 
weight, p.o.),Group-III: Compound-I (20 
mg/kg body weight, p.o.),Group-IV: 
Compound-II (20 mg/kg body weight, 
p.o.),Group-V: Compound-III (20 mg/kg 
body weight, p.o.). The animals were 
introduced into a rectangular box with an 
inclined plane by which the mice can 
escape from the box and the mice that 
escaped within 5 min from the rectangular 
box were selected for this test. 30, 60, 90 
and 120 minutes after administration of 
normal saline or diazepam (standard drug) 
or Benzopyran-2-one derivatives, the 
animals (n=6) were placed in the box and 
the number of mice remaining in the box 
after 5 min of test duration in each group 
was noted [82, 83]. 
 
GABA assay by paper chromatography 
method 
The GABA levels in serum were assayed 
by paper chromatography method as 
mentioned by Mishraa, et.al., with some 
modifications. The serum sample (100 µl) 
was added to 1.5 ml of absolute alcohol 
and centrifuged at 3000 g for 15 minutes. 
The upper layer was aspirated and 0.3 ml 
was put on Whatman’s filter paper which 
was dipped in mobile phase solution (n-
butanol, glacial acetic acid, water) until the 
mobile phase is sufficiently run in upward 
direction of the paper then subsequently 
the filter paper was dried in air. Thereafter, 
ninhydrin salt solution was sprayed on 
chromatography paper for spot 
development and heated at 65oC for 10 
minutes [84]. The spot, developed due to 
chromatographic mobility of GABA, was 
cut and put in 3 ml solution of absolute 
alcohol for elution. The optical density of 
eluted sample was taken on a 
spectrophotometer at wavelength of 509 
nm and compared with standard GABA 
solution. 
 
Spontaneous Motor Activity (SMA) 
Actophotometer test 
Wistar albino mice of either sex weighing 
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groups, i.e., Group-I: Control – 1 % 
sodium CMC (5 ml/kg p.o.),Group-II: 
Standard - Diazepam (1 mg/ kg body 
weight, p.o.),Group-III: Compound-I (20 
mg/kg body weight, p.o.),Group-IV: 
Compound-II (20 mg/kg body weight, 
p.o.),Group-V: Compound-III (20 mg/kg 
body weight, p.o.).Spontaneous motor 
activity was evaluated using 
actophotometer [85]. Mice were grouped 
of 6 each and treated with 1% sodium 
CMC (5 ml/kg p.o.) or the Benzopyran-2-
one test drugs i.e. comp-I, comp-II and 
comp-III (20 mg/kg p.o.) or received 
diazepam as standard drug (1 mg/kg p.o.). 
Activity (number of counts) was recorded 
30 min after treatment for 10 min. SMA 
measurements (number of counts) started 
30 min after the administration of the test 
drug and the results were compared with 
those of control. The experiments were 
repeated at an interval of 30 min, for a 
total of 120 mins. (i.e. at 0, 30, 60, 90 and 
120 mins). Results of the treated groups 
were compared with those of control group 
at each time interval.  
 
Skeletal Muscle Relaxant Activity 
Rotarod test 
Wistar albino mice of either sex weighing 
between 20-25 g were divided into five 
groups, i.e., Group-I: Control – 1 % 
sodium CMC (5 ml/kg p.o.),Group-II: 
Standard - Diazepam (1 mg/ kg body 
weight, p.o.),Group-III: Compound-I (20 
mg/kg body weight, p.o.),Group-IV: 
Compound-II (20 mg/kg body weight, 
p.o.),Group-V: Compound-III (20 mg/kg 
body weight, p.o.).Spontaneous motor 
activity was evaluated using 
actophotometer. Mice were grouped of 6 
each and treated with 1% sodium CMC (5 
ml/kg p.o.) or the Benzopyran-2-one test 
drugs i.e. comp-I, comp-II and comp-III 
(20 mg/kg p.o.) or received diazepam as 
standard drug (1 mg/kg p.o.).Mice were 
placed on a horizontal wooden rod (32 mm 
diameter) rotating at a speed of 16 rpm 
[86, 87]. The animals remaining on the rod 
for 3 min or more in two successive trials 
were selected for the test and were divided 
into 5 groups of 6 animals each. The 
animals were treated with 1% sodium 
CMC (5 ml/kg p.o.) or standard drug 
diazepam (1 mg/kg p.o.) or Benzopyran-2-
one derivatives (20 mg/kg p.o.) and after 
30 min of treatment animals were placed 
on the rod to note the time taken for the 
mice to fall from the rotating rod.  
 
Analgesic Activity 
Eddy’s Hot Plate method 
Wistar albino mice of either sex weighing 
between 20-25 g were divided into five 
groups i.e., Group-I: Control – 1 % 
Sodium CMC (5 ml/kg p.o.), Group-
II:Standard - Pentazocine (10 mg/kg body 
weight, i.p.), Group-III:Compound-I (20 
mg/kg body weight, p.o.),Group-IV: 
Compound-II (20 mg/kg body weight, 
p.o.),Group-V:Compound-III (20 mg/kg 
body weight, p.o.). The test was carried 
out using Eddy’s hot plate apparatus, 
where the temperature was set at 55 ± 10 
C. Mice of either sex weighing between 
20-25 g which showing cut off time below 
15 sec were selected for test and divided 
randomly into five groups [88, 89, 90]. 
The mice were placed on hot plate and 
recorded the reaction time in second/s for 
licking of hind paw or jumping with cut 
off time of 15 seconds to avoid tissue 
injury. The reaction time following the 
administration of the test derivatives, 
standard drug (pentazocine) and control 
saline vehicle were measured at 0, 30, 60, 
90 and 120 minutes respectively. 
 
Tail clip method 
Wistar albino mice of either sex weighing 
between 20-25 g were divided into five 
groups i.e., Group-I: Control – 1 % 
Sodium CMC (5 ml/kg p.o.), Group-
II:Standard - Pentazocine (10 mg/kg body 
weight, i.p.), Group-III:Compound-I (20 
mg/kg body weight, p.o.),Group-IV: 
Compound-II (20 mg/kg body weight, 
p.o.),Group-V:Compound-III (20 mg/kg 
body weight, p.o.) [91]. All the mice were 
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the base of the tail with its jaws sheated 
with rubber tubing. The pressure exerted 
by the clip was so adjusted that it was just 
sufficient to make all control mice 
respond. Those animals that did not show 
efforts to dislodge the clip within 15 sec 
were not used for the experiment. The 
mice showing positive response were 
divided into 5 groups of 6 each. The tail 
clip was applied 0, 30, 60, 90 and 120 min 
after oral administration of the 
Benzopyran-2-one derivatives i.e., comp-I, 
comp-II and comp-III at a dose of 20 
mg/kg each or pentazocine (10 mg/kg). 1% 
Sodium CMC (5 ml/kg p.o.) was used as 
control. It was considered a positive 
analgesic response if there was no attempt 
to dislodge the clip within 15 sec in any of 
four consecutive trials. 
 
Statistical Analysis 
The results are expressed as the mean ± 
S.E.M. The results obtained from the 
present study were analyzed by using one-
way Analysis of Variance (ANOVA) 
followed by Dunnett’s multiple 
comparison tests. Data was computed for 
statistical analysis by using Graph Pad 
Prism 5.0 software and compared with the 
vehicle control group. P values less than 




Acute Toxicity Study 
The acute oral toxicity study was 
performed as per the OECD guidelines 
423 by Following up and down method it 
has been found that all three Benzopyran-
2-one (coumarin) derivatives i.e., comp-I, 
comp-II and comp-III were toxic above a 
dose of 200 mg/kg. Hence, 20 mg/kg dose 




PTZ induced seizure model 
Results of anticonvulsant activity in PTZ 
induced seizure model is shown in Table 
1. For anticonvulsant activity diazepam 
(1mg/kg, p.o) was used as a standard drug 
which showed significant prolongation of 
onset of seizures to 655.3±20.49 sec and 
reduced the duration of seizures to 
0.50±0.28 sec. Also, it showed a 100% 
protection from mortality when compared 
with the control which showed onset of 
seizure at 15.99±1.66 sec and duration of 
seizures for 18.01±0.40 sec with 100% 
mortality. All the test compounds were 
found to be statistically significant at value 
P < 0.0001 and P <0.001. But 
anticonvulsant activity of comp-II 
(66.66±0.47 % mortality protection) was 
found to be better than comp-I and comp-
III with regard to prolongation of onset of 
seizures, reduction of duration of seizures 
and % of mortality protection.  
 
Anxiolytic Activity  
Evasion test 
Number of animals (mice, n=6) remaining 
in the box during exploratory period of 5 
min after drug administration were 
counted. Here mean of two values were 
taken. Results of evasion test to test the 
exploratory behaviour is shown in Table 2. 
For Evasion test, diazepam (1 mg/kg, p.o.) 
was used as a standard drug which showed 
a significant anxiolytic effect after 30 min 
(no of mice remaining in box – 4.0±1.0 i.e 
mean of two values 4 and 4), 60 min 
(06±0.0 mice remaining in box – i.e. mean 
of 6 and 6), 90 min (06±0.0 mice 
remaining in box – i.e. mean of 6 and 6)) 
and 120 min (4.5±0.50 mice remaining in 
box – i.e. mean of 4 and 5)) of drug 
administration when compared with 
control (0 mice remaining in box) 
throughout the test period. It was found 
that all three derivatives i.e., comp-I, 
comp-II and comp-III possesses the anti-
anxiety activity in mice. All the test 
compounds were found to be statistically 
significant at P < 0.0001 and P <0.001 
values. comp-II was found to be better 
than comp-I and comp-III. 
 
GABA Assay 
Table 3 showing the GABA levels in all 
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derivatives were assayed and compared to 
that of standard GABA solution. GABA 
levels were significantly increased in the 
treated group as compared to that of 
control (Table 5). GABA levels in the 
groups treated with test compounds were 
found to be less than that of the standard 
GABA solution (0.1 ug/ml). GABA levels 
in Diazepam treated animals were near to 
standard GABA solution (769.23 
pmol/ml). The GABA levels was found to 
be 307.69, 615.38, 461.53 pmol/ml in 
groups treated with comp-I, comp-II and 
comp-III respectively. Thus, GABA levels 
of group treated with comp-II was found to 
be higher than that of comp-I and comp-
III. 
 
Spontaneous Motor Activity (SMA) 
Actophotometer Test 
Results of SMA are shown in Table 4 for 
SMA diazepam (1 mg/kg, p.o) was used as 
a standard drug. Diazepam showed a 
significant decrease in locomotor activity 
after 30 min (37.25±2.28 counts) and 
continued its effect at 60 min (12.25±1.65 
counts), 90 min (17.25±2.72 counts) and 
120 min (22.75±2.46 counts) when 
compared with control at 30 min 
(305.3±7.95 counts), 60 min (260.0±25.46 
counts), 90 min (277.5±20.87 counts) and 
120 min (307.8±7.25 counts). It was found 
that all three Benzopyran-2-one 
derivatives i.e., comp-I, comp-II and 
comp-III decreased the spontaneous motor 
activity in mice and all the test compounds 
were found to be statistically significant 
with a P values less than 0.0001 
(P<0.0001) where comp-II was found to 
be better than comp-I and comp-III. 
 
Skeletal Muscle Relaxant Activity  
Rotarod test 
Time taken by the mice in sec to fall from 
the rod in 180 sec (3 min) of trial period 
after 60 min of drug administration. 
Results of rotarod test to test the skeletal 
muscle relaxation is shown in Table 5, for 
skeletal muscle relaxation diazepam (1 
mg/kg, p.o) was used as a standard drug, 
which showed a significant relaxation of 
skeletal muscles after 30 min (9.858±0.58 
sec required for mice to fall from rod) of 
drug administration when compared with 
the control (165.2±6.12 sec required for 
mice to fall from rod). It was found that all 
three derivatives i.e., comp-I, comp-II and 
comp-III possesses the skeletal muscle 
relaxant activity in mice, where comp-II 
was found to be better (P<0.0001) than 
comp-I and comp-III. 
 
Analgesic Activity 
Eddy’s Hot Plate Method 
The reaction time of the mice is shown in 
Table 6. at different time interval. In hot 
plate method pentazocine was used as 
standard drug which showed significant 
increase in reaction time to the heat 
stimulus. The values were found to be 
significant at 30 min (4.54±0.82 sec) 60 
min (7.39±0.93 sec), 90 min (7.94±0.61 
sec) and 120 min (5.30±0.46 sec) after 
treatment, when compared with control 
(1.61±0.24, 1.62±0.37, 1.66±0.27, and 
1.62±0.30 sec after 30, 60, 90 and 120 min 
respectively). The test Benzopyran-2-one 
derivatives i.e., comp-I, comp- II and 
comp-III showed significant increase in 
the reaction time at 60 min and 90 min 
after drug administration. These entire test 
compounds were found to be statistically 
significant at value P < 0.0001. It was 
found that all three Benzopyran-2-one 
derivatives possesses analgesic activity 
where comp-II was found to be better than 
comp-I and comp-III. 
 
Tail Clip Method 
The reaction time of the mice is shown in 
Table 7 at different time interval. In tail 
clip method pentazocine was used as 
standard drug which showed significant 
increase in reaction time to the pain 
stimulus. The values were found to be 
significant at 60 min after treatment 
(9.54±0.63 sec) and 90 min (10.90±0.68 
sec) when compared with control 
(1.51±0.14 and 1.58±0.025 sec at 60 and 
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found to be statistically significant at value 
P < 0.0001. It was found that all three 
Benzopyran-2-one derivatives possess 
analgesic activity where comp-II was 
found to be better than comp-I and comp-
III.
 
Results (Tables and Figures) 
Table 1: Effect of Benzopyran-2-one derivatives on pentylenetetrazole (PTZ) - induced 
seizure in mice. 










Control (1 % sodium 
CMC) + PTZ 
5 ml/kg+ 
90 mg/kg 
15.99 ± 1.66 18.01± 0.40 0.00 ± 0.00 
2 Diazepam 1 655.3 ± 20.49*** 0.50 ± 0.28*** 100.0 ± 0.00*** 
3 Compound-I 20 54.59 ± 2.96* 9.08 ± 0.65*** 0.00 ± 0.00 
4 Compound-II 20 46.08 ± 2.71 7.69 ± 0.47*** 66.66 ± 0.47*** 
5 Compound-III 20 50.09 ± 3.95 8.52 ± 0.68*** 0.00 ± 0.00 
  P value 0.0001 0.0001 0.0001 




 p < 0.001 and 
***
 p < 0.0001 as compared to control (ANOVA followed by 
Dunnett’s test) 
 









Number of animals (n=6) remaining in 
the box after 5 min (mean of two values) 
30 min 60 min 90 min 120 min 
1 
Control (1 % sodium 
CMC) 
5 ml/kg 0 0 0 0 
2 Diazepam 1 4.0 ± 1.0* 6.0 ± 0.0*** 6.0 ± 0.0*** 4.5 ± 0.50** 
3 Compound-I 20 1.5 ± 0.50 3.5 ± 0.50** 2.5 ± 0.50** 1.5 ± 0.50 
4 Compound-II 20 2.5 ± 0.5 4.0 ± 0.0*** 6.0 ± 0.0*** 2.5 ± 0.50* 
5 Compound-III 20 2.0 ± 0.0 3.5 ± 0.50** 2.5 ± 0.50** 2.0 ± 0.0* 
 P value  0.0272 0.0004 0.0002 0.0037 




 p < 0.001 and 
***
 p < 0.0001 as compared to control (ANOVA followed by 
Dunnett’s test) 
 
Table 3: Effect of Benzopyran-2-one derivatives on serum GABA levels in mice. 
Sl.No. Treatment Optical Density (OD) at 509 nm GABA levels (pmol/ml ) 
1 Control 0.03 214.28 
2 Diazepam 0.10 769.23 
3 Compound-I 0.04 307.69 
4 Compound-II 0.08 615.38 
5 Compound-III 0.06 461.53 
6 Std. GABA 0.13 1000.00 
O.D. of test X 1000 = pmol/ml
67
 
O.D. of std 
Note: 1ug = 1000 pg. Hence, to convert values into picogram (pg), values must be multiplied 
by 1000. 
O.D. of standard GABA solution (0.1ug/ml) = 0.13 
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GABA levels of all Benzopyran-2-one derivatives was assayed and compared with the 
level of standard GABA solution (0.1ug/ml) 







0 min 30 min 60 min 90 min 120 min 
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 P value  0.3788 < 0. 0001 < 0.0001 < 0.0001 < 0.0001 
All values are expressed as mean ± S.E.M. (n=6). 
***
 p < 0.0001 as compared to control (ANOVA followed by Dunnett’s test). 
 
Table 5: Effect of Benzopyran-2-one derivatives on skeletal muscle relaxation in mice 
(Rotarod test). 
Sl.No. Treatment Dose (mg/kg p.o.) Time in seconds ( To fall from rotarod ) 
1 Control (1 % sodium CMC) 5 ml/kg 165.2 ± 6.12 
2 Diazepam 1 9.858 ± 0.58*** 
3 Compound-I 20 143.9 ± 5.05** 
4 Compound-II 20 105.8 ± 1.95*** 
5 Compound-III 20 121.6 ± 3.79*** 
 P value  < 0.0001 




 p < 0.001 and 
***
 p < 0.0001 as compared to control (ANOVA followed by 
Dunnett’s test) 
 
Table 6: Effect of Benzopyran-2-one derivatives in mice by Eddy’s hot plate test. 
Sl. No. Treatment 
Dose mg/kg 
(p.o.) 
0 min 30 min 60 min 90 min 120 min 
1 
Control (1 % 
sodium CMC) 













































 P Value  0.9921 0.0004 0.0002 < 0.0001 0.0002 
All values are expressed as mean ± S.E.M. (n=6). 
 ***
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Table 7: Effect of Benzopyran-2-one derivatives in mice by Haffner’s tail clip test. 
Sl. No. Treatment 
Dose mg/kg 
(p.o.) 
0 min 30 min 60 min 90 min 120 min 
1 
Control (1 % 
sodium CMC) 













































 P Value  0.7479 0.0002 < 0.0001 < 0.0001 < 0.0001 
All values are expressed as mean ± S.E.M. (n=6). 
 ***
 p < 0.0001 as compared to control (ANOVA followed by Dunnett’s test) 
 
 
Figure 1: Effect of Benzopyran-2-one derivatives on pentylenetetrazole (PTZ), induced 
seizure in mice. 
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Figure 6: Effect of Benzopyran-2-one derivatives in mice by Haffner’s tail clip test. 
 
DISCUSSION 
The present study deals with the 
investigation of neuropharmacological 
profile of newly synthesized Benzopyran-
2-one derivatives. The most frequent step 
in evaluating drug action on the CNS is to 
observe the behavior of the test animals. 
The neuropharmacological profiles of 
Benzopyran-2-one derivatives (i.e., comp-
I, comp-II and comp-III) were evaluated 
by performing the anticonvulsant activity 
by PTZ induced convulsion model, 
anxiolytic activity by evasion test, SMA 
by actophotometer test, motor coordination 
by rotarod test and analgesic activity by 
Eddy’s hot plate method and Haffener’s 
tail clip method. 
 
In the present study, testing for 
anticonvulsant effects of Benzopyran-2-
one derivatives by PTZ induced 
convulsant model was used. 
Anticonvulsant drugs those are effective 
against the most common forms of 
epileptic seizures, namely partial and 
generalized tonic-clonic seizures, act 
either by: 
Reducing or limiting the sustained 
repetitive firing of neurons, an effect 
mediated by promoting or prolonging the 
inactivated state of voltage- activated Na
+
- 
channels, thereby reducing the ability of 
neurons to fire at high frequencies. 
 
Enhancing and facilitating GABA-
mediated synaptic transmission and 
inhibition, an effect mediated either by a 
pre- or post- synaptic action. In presence 
of GABA, the GABAA receptor is opened, 
thus allowing an influx of Cl
-
 ions, which 
in turn increases membrane polarization. 
 
Some anticonvulsant drugs also act by 
reducing the metabolism of GABA. 
 Some act at GABAA receptors, 
enhancing Cl
-
 ion influx in response to 
GABA or by promoting GABA 
release. 
 Agents that are effective against 
absence seizure, act by reducing or 
limiting the flow of Ca
2+
 through T-
type of voltage- activated Ca
2+
 






Drugs that reduce PTZ induced 
seizures act by; 
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Results obtained from the PTZ induced 
seizure model clearly indicate significant 
prolongation in the onset of seizures and a 
significant reduction in the duration of 
seizures for all three Benzopyran-2-one 
derivatives used for present study, i.e., 
comp-I, comp-II and comp-III. Comp-II 
showed a significant reduction in the 
mortality rate of mice, whereas, comp-I 
and comp-III did not show any protection 
of mortality in mice.  
 
In the present study, GABA levels were 
assayed to confirm the effect of test 
compounds on GABA. The GABA levels 
were significantly increased in the groups 
treated with test compounds and diazepam 
as compared to that of control. GABA 
levels in the treated groups with test 
compounds were found to be less than that 
of the standard GABA solution. 
 
Therefore, we can conclude that the 
Benzopyran-2-one derivatives (i.e., comp-
I, comp-II and comp-III) may have exerted 
anticonvulsant effects by enhancing 
GABAergic inhibitory neurotransmission 
similar to that of diazepam, which leads to 
opening of Cl
-
 ion channel and influx of 
Cl
-
 ions causing membrane 
hyperpolarisation or by decreasing the 
degradation of GABA [92].
 
But, the exact 
mechanism for increase in GABA content 
could not be reported in this study and 
remains to be explored.  
 
Evasion test was used to test the effect of 
Benzopyran-2-one derivatives on 
exploratory behaviour. There was 
significant increase in the number of 
animals remaining in the box after 
treatment with Benzopyran-2-one 
derivatives. The results obtained from the 
evasion test of all three Benzopyran-2-one 
derivatives indicate that these derivatives 
have depressant action on the CNS [94]. 
Diazepam was used as a standard 
reference drug for the evasion test. A 
significant reduction in exploratory 
behaviour exemplified in the evasion test 
by all three Benzopyran-2-one derivatives 
(i.e., comp-I, comp-II and comp-III) 
indicate a CNS depressant action and a 
strong indication of anxiolytic action as 
produced by diazepam. Anxiolytics are 
known to exert pharmacological action by 
causing an increase in the GABA content 
in the cerebral hemisphere in mice [95]. 
Hence, we can conclude that all three 
Benzopyran-2-one derivatives (i.e., comp-
I, comp-II and comp-III) used in present 
study act through BDZ-GABA receptors, 
i.e., test derivatives might involve an 
action on GABAergic transmission like 
that of diazepam. 
 
Locomotor activity of the animals is one of 
the frequent step to evaluate the effect of 
drugs on CNS. SMA was assessed by 
using Actophotometer test. This model has 
been used in laboratory animals to 
evaluate the gross behavioral effects of the 
drugs. Locomotor activity is considered as 
an index of alertness and a decrease in 
locomotion reveals sedative effect [96]. 
The SMA is a measure of the levels of 
excitability of the CNS and this decrease 
may be closely related to sedation 
resulting from depression of the CNS [97]. 
The results obtained showed that the 
Benzopyran-2-one derivatives decreased 
the alertness and restlessness. There were 
neither tremors, twitches, convulsions nor 
strub tail response. No effects were noticed 
on alarm reaction, body posture, limb 
position, gait, righting reflex, muscle tone, 
pinna and corneal reflexes. From such 
observations, it is possible to conclude that 
the depressant effect of the Benzopyran-2-
one derivatives on locomotor activity was 
probably not due to a peripheral 
neuromuscular blockage [98]. Diazepam 
was used as a standard reference drug for 
spontaneous motor activity. Hence, we can 
conclude that all three Benzopyran-2-one 
derivatives (i.e., comp-I, comp-II and 
comp-III) act like that of diazepam which 
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From the results by Rotarod test, it is clear 
that all three Benzopyran-2-one 
derivatives (i.e., comp-I, comp-II and 
comp-III) used in present study showed 
significant relaxation of skeletal muscles 
as like that of diazepam. Hence, we can 
conclude that all the three Benzopyran-2-
one derivatives exert their relaxant effect 
on skeletal muscle by acting through a 
centrally mediated GABA inhibition of 
polysynaptic reflexes to skeletal muscles 
[95]. 
 
The analgesic activity of Benzopyran-2-
one derivatives (i.e., comp-I, comp-II and 
comp-III) was carried out by using Eddy’s 
hot plate and Haffner’s tail clip methods. 
The hot plate method was selected to 
investigate central analgesic activity, 
because it had several advantages, 
particularly the sensitivity to strong anti-
nociceptives and limited tissue damage 
[99]. Pentazocine was used as a standard 
reference drug in hot plate method which 
acts through opoid receptors and inhibit 
the neurogenic pain releasing substance 
[90]. The results of hot plate method 
showed siginificant increase in the reaction 
time to heat stimulus in same manner as 
like that of pentazocine. Hence, we can 
conclude that all the three Benzopyran-2-
one derivatives (comp-I, comp-II and 
comp-III) showed analgesic activity by in 
similar way to that of pentazocine. 
Haffener’s tail clip method is simple and 
has the advantage that the reflex 
mechanism on which it is based involves 
the higher centres. The animal has to 
identify exactly the place where the 
noxious stimulus is applied and it carries 
out coordinated movements to remove it 
[100]. In Haffner’s tail clip method, 
animals significantly prolonged the latency 
to dislodge the clip from their tail in 
treated group when compared with control 
group. Centrally acting analgesic drugs 
elevate pain threshold of animals towards 
heat and pressure [101]. All the three 
Benzopyran-2-one derivatives (i.e., comp-
I, comp-II and comp-III) showed 
significant analgesic effect on mechanical 
induced pains. Hence, the results from 
both analgesic tests showed a clear 
indication of a very potent analgesic 




From the obtained results of the present 
study, we can conclude that the newly 
synthesized Benzopyran-2-one derivatives, 
i.e., 7-(2-(m-nitro)-phenyl thiazolidinyl)-4-
methyl benzopyran-2-one (comp-I), 7-(2-
(o,p-dichloro)-phenyl thiazolidinyl)-4-
methyl-benzopyran-2-one (comp-II) and 7-
(2-(p-methyl)-phenyl thiazolidinyl)-4-
methyl-benzopyran-2-one (comp-III), 
possess neuropharmacological properties 
which includes CNS depressant activity by 
SMA, skeletal muscle relaxant activity, 
analgesic activity and anticonvulsant 
activity. Elevation of GABA levels in 
treated groups with Benzopyran-2-one 
derivatives further supported the CNS 
depressant activity. The overall effect of 
comp II was found to be better than that of 
comp I and comp III. Further evaluation of 
detail mechanism pathway involved in all 
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